1. Case-cohort design as an efficient approach to evaluating COVID-19 vaccine effectiveness, waning, heterologous immune effect and optimal dosing interval.
- Author
-
Fisman DN, Simmons AE, and Tuite AR
- Subjects
- Humans, Cohort Studies, Middle Aged, Male, Female, Ontario, Adult, Aged, Vaccination methods, Immunization Schedule, Young Adult, Adolescent, Proportional Hazards Models, COVID-19 prevention & control, COVID-19 immunology, COVID-19 epidemiology, COVID-19 Vaccines immunology, COVID-19 Vaccines administration & dosage, Vaccine Efficacy, SARS-CoV-2 immunology
- Abstract
Though widely applied in other epidemiological fields, the case-cohort study design has seen little application in the field of vaccinology. Case-cohort studies use probabilistic sampling and reweighting to draw inferences about effects (in this case vaccine efficacy) at the population level in an efficient manner. The SARS-CoV-2 pandemic was met with high vaccine uptake, and high rates of population testing prior to the emergence of Omicron variants of concern, in Ontario, Canada, providing an ideal environment for application of case-cohort methodology. We combined a population-based case line list and vaccination database for the province of Ontario between December 2020 and October 2021. Risk of infection after vaccination was evaluated in all laboratory-confirmed vaccinated SARS-CoV-2 cases, and a 2 % sample of vaccinated controls, evaluated using survival analytic methods, including construction of Cox proportional hazards models. Vaccination status was treated as a time-varying covariate. First and second doses of SARS-CoV-2 vaccine markedly reduced risk of infection (first dose efficacy 68 %, 95 % CI 67 %-69 %; second dose efficacy 88 %, 95 % CI 87-88 %). In multivariable models, extended dosing intervals were associated with lowest risk of breakthrough infection (HR for redosing 0.64 (95 % CI 0.61-0.67) at 6-8 weeks). Heterologous vaccine schedules that mixed viral vector vaccine first doses with mRNA second doses were significantly more effective than mRNA only vaccines. Risk of infection largely vanished during the time period 4-6 months after the second vaccine dose, but rose markedly thereafter. We conclude that a case-cohort design provided an efficient means to identify strong protective effects associated with SARS-CoV-2 vaccination in real time, and also served to quantify the timing and magnitude of infection breakthrough risk in the same cohort. Heterologous vaccination and extended dosing intervals improved the durability of immune response., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: David Fisman reports financial support was provided by Canadian Institutes of Health Research. David Fisman reports a relationship with Pfizer Inc that includes: consulting or advisory. David Fisman reports a relationship with Seqirus Inc that includes: consulting or advisory. David Fisman reports a relationship with AstraZeneca Canada Inc that includes: consulting or advisory. David Fisman reports a relationship with Merck & Co Inc that includes: consulting or advisory. David Fisman reports a relationship with Sanofi Pasteur Inc that includes: consulting or advisory. David Fisman reports a relationship with Elementary Teachers’ Federation of Ontario that includes: paid expert testimony. David Fisman reports a relationship with Ontario Nurses’ Association that includes: paid expert testimony. Ashleigh Tuite reports a relationship with Public Health Agency of Canada that includes: employment. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier Ltd.)
- Published
- 2024
- Full Text
- View/download PDF